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Abstract  
BACKGROUND: Pro12Ala (rs1801282) is a common polymorphism of the human PPAR-γ gene. Studies have 
demonstrated conflicting results about its association with T2DM worldwide. There are no reports about such 
possible association among Iraqi people.   
OBJECTIVES:  This study aims at finding out whether having the mutant allele (Ala12) might be associated with 
T2DM among Iraqi people. 
METHODS: One hundred and ninety-two Arabic Iraqi adult subjects (97 with T2DM and 95 controls) were 
genotyped using PCR- RFLP. Clinical, anthropometrical and biochemical variables were compared regarding the 
Pro12Ala genotypes. 
RESULTS: About 5.67% of people with diabetes were carriers of the (Ala12) allele versus 9.47% of controls. 
Allelic and genotypic frequencies were not statistically different among diabetics and controls [(2= 1.99, p= 0.16) 
and (2= 2.17, p= 0.14)]. Age, BMI and smoking- but not Pro12Ala - were independent risk factors for T2DM in 
our subjects. Pro12Ala was not associated with T2DM (Odd's ratio 0.55, 95% CI 0.23- 1.32, p= 0.14).  
CONCLUSIONS: Our study revealed a relatively high frequency of the Ala12 allele among Arabic Iraqis. These 
frequencies did not significantly differ between diabetics and controls indicating the absence of association of 
Pro12Ala with T2DM among Iraqis. 
 
 
 
 
Introduction 
 
Diabetes Mellitus (DM) is a heterogeneous 
group of metabolic disorders that occur as an ultimate 
result of defective endogenous insulin secretion 
and/or action [1]. The genetic contribution in the 
pathogenesis of type 2 diabetes mellitus (T2DM) is 
remarkable given the inheritance is seen in families, 
the high prevalence rates of the disease in certain 
ethnic groups compared to others and the difference 
in the concordance rates when monozygotic twins are 
compared to dizygotic ones [2] [3].  The genetic 
background of T2DM has shown to be a cocktail as 
described by Freeman and Cox who suggested that 
understanding the basis of the genetic traits of T2DM 
can help identify new therapeutic targets, which 
currently represents one of the most promising 
strategies for the long-term treatment success [4]. 
Scientists have used their tools for exploring 
the genetic background of T2DM including “Genome 
Scans” and “Association studies”. The association 
studies, including Genome Wide Association Studies 
(GWAS), are case-control studies that investigate the 
relationship of particular disease status with certain 
alleles, genotype (or haplotype) or most commonly a 
set of single-nucleotide polymorphisms (SNPs) [4] [5] 
[6] [7]. The GWAS(s) which were first successfully 
conducted in 2005 is a major tool for identifying 
different biological pathways, understanding the 
pathophysiology of several complex (multifactorial) 
diseases and developing drug therapies [7]. They 
typically conduct the first analysis in an exploration 
cohort and then validate the most significant genetic 
findings (mainly SNPs) in an independent validation 
cohort [8].Several association studies have identified 
some key genes for human T2DM susceptibility of 
which the peroxisome proliferator-activated receptor 
gamma (PPAR-γ) and the KCNJ11 are the most 
promising genes [9] [10]. However, using the 
candidate gene approach, other several genes have 
been recently confirmed as susceptibility genes like 
CAPN10, HNF4A, TCF7L2, BCL11A, MTNR1B, 
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NOTCH2/ADAM S30, DCD, VEGFA, GCK, FTO, 
HHEX/IDE, JAZFI, KCNQ1, CYP3A4, and others [11].  
Peroxisome proliferator-activated receptors 
are ligand-activated transcription factors that belong to 
the nuclear hormone receptor superfamily
 
[12]. Their 
activation through their ligands binding leads to 
augment the expression of many genes especially 
those involved in lipid metabolism and energy 
homeostasis
 
[13] [14]. There are three well-identified 
types of PPARs; PPAR α, PPARδ (or PPARβ) and 
PPARγ. The DNA- binding domains of the three 
subtypes are about 80% identical [15].  
Human PPAR γ gene is located on 
chromosome 3 (3p25), and it spans a genomic 
segment of around 150 kb. It consists of 9 exons (A1, 
A2, B and 1-6) that code for the two major isoforms of 
PPAR γ mRNA and protein (PPAR γ1 and PPAR γ2) 
via the use of different promoters and alternative 
splicing [16].  
In humans, PPAR γ2 is mainly expressed in 
the adipose tissue, and it is a critical transcriptional 
factor in the regulation of adipocytes differentiation 
and the expression of many genes that are 
responsible for lipogenesis and insulin signalling [17]. 
PPAR γ agonists –whether natural like 
polyunsaturated fatty acids or synthetic like the 
antidiabetic drugs thiazolidinediones- have been 
shown to improve the overall body insulin sensitivity in 
a variety of insulin resistant experimental animals and 
diabetic humans [18] [19].
 
 
A common C→ G polymorphism of PPAR-γ 
gene results in a proline to alanine substitution at the 
codon 12 of the gene (Pro12Ala) with a reduced 
transcriptional activity of the resultant protein [20] [21]. 
The minor allele (Ala12 allele) frequency of this 
common gene variant is widely variable worldwide. It 
was found to range from 5.9% to 21.6% among 
Caucasian ethnicities, and from 1.7% to 9.3% among 
people of East Asian descent such as Chinese and 
Japanese [22].  
There has been conflicting results about the 
association of Pro12Ala mutation of PPAR- γ gene 
with T2DM in different populations [23] [28]. We 
hypothesize that this variant is linked to the risk of 
T2DM in Iraqi people as well due to its possible 
impacts on insulin action and/or signaling pathways 
and that the inconsistent  findings concerning its 
association with diabetes around the world is a 
reflection of the multifaceted interactions between this 
polymorphism and various environmental factors 
(including the different fatty acids contents in people 
diet world-wide) and/or between this sequence 
variation and other genetic factors. 
In fact, there have been no studies on the 
association of Pro12Ala (rs1801282) of PPAR-γ gene 
with T2DM in Iraqi people. So, this study aims to find 
out whether having its mutant allele (Ala12) is 
associated to T2DM in a representative sample of 
adult Iraqi people of Arabic ethnicity.  
 
 
Materials and Methods 
 
This study has been approved by the "Human 
Research Ethical Committee" of Ninevah Health 
Directorate, Ninevah, Iraq in April 2013. Written 
consents were obtained from all participants after 
explaining the research objectives, plans and 
procedures during a brief interview and the work was 
conducted by the ethical standards of Declaration of 
Helsinki II.  
This age, sex and ethnicity matched case-
control study was designed to investigate the 
association of the Pro12Ala mutation of PPAR-γ gene 
with T2DM among 192 adult Iraqi people over a 
period of 7 months from May 3
rd
. Through November 
30
th,
 2013. It involved 97 (57males and 40 females) 
unrelated adult (34-71 years old) Arabic Iraqi T2DM 
patients with variable duration and onset of diabetes 
consulting Al-Wafaa Center of Diabetes Care and 
Education in Western Mosul, Ninevah, Iraq and 95 
(51males and 44 females) apparently healthy 
unrelated non-diabetic Iraqi adult (30-70 years old) 
subjects with negative family history of diabetes 
mellitus.   
Diabetes mellitus was defined by physician's 
diagnosis according to the American Diabetes 
Association (ADA) criteria; a fasting plasma glucose 
(FPG) level ≥ 7 mmol/l (126 mg/dl), two hours 
postprandial glucose (2h PG) level ≥ 11.1 mmol/l (200 
mg/dl) or use of diabetes medications [29]. Iraq is a 
multi-ethnic, multi-religious and multi-nationalities 
country. This study focused only on Arabic residents 
of different urban areas of Mosul City, Ninevah 
Province, Northern Iraq without a history of mixed 
marriages with other ethnicities till the third 
generation.  
The diabetic patients who formed Group (I) 
were recruited for history taking, physical examination 
and blood collection, when ready, after overnight 
fasting. Resting blood pressure was measured in 
sitting position, and anthropometric measurements 
were taken including height and weight with shoes off 
and light clothes. Body mass index (BMI) was 
calculated as weight (kg)/ height (m)
2
. Patients were 
excluded from the study when having T1DM, previous 
history of ketoacidosis, other than Arabic ethnicities, 
history of liver or kidney diseases (or any malignancy) 
or being involved in another clinical or interventional 
study.  
The subjects who formed Group (II) were 
basically the relatives of non- diabetic patients 
admitted for surgical operations at Al-Joumhori 
Teaching Hospital in Western Mosul in addition to the 
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members of the nursing staff of the hospital. They 
have all fulfilled the inclusion criteria and agreed to 
participate in this study.  
To be considered as "Controls", subjects were 
required to be over the age of 30 years, having a 
negative personal and family history of diabetes 
mellitus with their fasting plasma glucose being in the 
normal range (3.33-5.56 mmol/l) following overnight 
fasting. Any history of previous abnormal glucose 
homeostasis and current FPG > 5.56 mmol/l was 
enough to exclude the subject from the control group. 
Other exclusion criteria for being among the controls 
included the history of liver or kidney diseases, history 
of current or recent participation in an interventional 
study or drug abuse. History was taken from control 
subjects; anthropometric parameters were measured, 
resting blood pressure was recorded, and blood was 
aspirated.  
Plasma glucose was estimated manually at 
the laboratory of Biochemistry, Mosul Medical College 
relying on glucose oxidase-peroxidase method, which 
is highly specific for D-glucose [30] using a kit 
supplied by Randox Ltd (England). The genetic work 
has been conducted in the PCR laboratory of Ibn Al-
Atheer Teaching Hospital, Eastern Mosul. Genomic 
DNA was extracted from EDTA-treated whole blood 
samples using ReliaPrep
TM
 Blood gDNA MiniPrep 
System (Promega Corporation, USA) following the 
manufacturer's protocol. All T2DM patients and 
controls were genotyped for the Pro12Ala of PPARG 
gene using PCR-based restriction fragment length 
polymorphism (PCR-RFLP) assay as designed by 
Hamann et al. [31]. A 306 bp DNA sequence 
embracing the ambiguity site (cca→gca) at codon 12 
was first amplified using primers supplied by 
(GenScript, USA) as forward:  
5ˊ-GCCAATTCAAGCCCAGTC-3ˊ  
and reverse:  
5ˊ-CGTCCCCAATAGCCGTATC-3ˊ 
Amplification was done over 35 cycles in a 
final volume of 25 µl using 12.5 µl of 2XQiagen's PCR 
Master Mix (containing MgCl2 at final concentration of 
3mM and 5 units/µL HotStar Taq Plus DNA 
polymerase), 0.5 µl of each of forward and reverse 
primers (10 µM), 9µl of RNase- free water and 2.5 µl 
(average 300 ng) of DNA. The thermal conditions 
used for the amplification of the rs1801282 in our 
subjects are shown in Table 1. 
Table 1: Thermal conditions to amplify Pro12Ala for 
subsequent RFLP 
CONDITION TEMPERATURE TIME 
Initial denaturation 95˚C 5 min 
Denaturation 95˚C 30 sec 
Annealing 60˚C 90 sec 
Extension  72˚C 30 sec 
Final extension 68˚C 10 min 
Final volume=  25 μl, cycles= 35 
 
Following PCR, amplicons (306 bp) were 
subjected to digestion by a specific restriction 
endonuclease where the C/G variation creates a 
restriction site for HgaI enzyme. The recognition site 
for HgaI is the following: 
5ˊ- G A C G C (N) 5      …3ˊ 
3ˊ- C T G C G (N) 10      …5ˊ 
  
 Ten-µl of PCR products were digested with 3 
units of HgaI (New England Biolabs, UK) in a total 
reaction volume of 50 µl containing 5 µl of 10X 1.1 
NEBuffer (10 mM Bis Tris Propane-HCl, 10 mM 
MgCl2, 1 mM dithiothreitol, pH 7.0 at 25°C) at 37C° for 
60 minutes. The reaction was terminated by enzyme 
inactivation at 65°C for 20 min. DNA fragments were 
separated on 2% agarose gel stained with SYBR 
®
 
Safe DNA Gel Stain (Promega, USA) following 
standard gel electrophoresis, visualised on the UV 
transilluminator and photographed. Control DNA 
samples (wild-type CC, heterozygous mutant CG and 
homozygous mutant GG) whose genotypes were 
already confirmed by sequencing (primer extension) 
were subjected to the same PCR_RFLP reactions, 
and their digestion products were used in the 
electrophoretic runs for the confirmation of the 
samples genotypes.  
 
 Statistical Analysis 
Standard statistical methods were used to 
determine the mean, standard deviation (SD) and 
range (minimum-maximum). One Sample 
Kolmogorov- Smirnov Test (two-tailed) was used to 
investigate the normality of distribution of the study 
variables. Two-tailed unpaired Student's t-test was 
used to compare the mean values of continuous 
variables among subjects in different groups when 
variables were normally distributed or otherwise 
replaced by Mann Whitney-U test to compare 
variables that did not follow the normal distribution 
pattern.  
Categorical variables were compared by Chi-
square (
2
), or by using Fisher's exact test if the 
number of observations within a cell was less than 
five. Obedience of Pro12Ala genotypes to the Hardey- 
Weinberg Equilibrium (HWE) was also assessed 
using χ 2 test. HWE calculator was obtained from 
http://www.tufts.edu. Logistic regression analysis was 
used to study the relation between T2DM as the 
dependent variable and other influencers (like 
Pro12Ala gene polymorphism) as the independent 
variables. Mantel- Hanszel test was used to calculate 
the Odd's ration for the association of Pro12Ala with 
T2DM and its 95
th
 CI. Differences between 
observations were considered non- significant at p > 
0.0.5. Analyses were carried out using the Statistical 
Package for the Social Sciences (SPSS Statistics, 
17.0). 
Results 
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Among the diabetic patients, using the One-
Sample Kolmogorov-Smirnov test, the age, body 
weight, BMI, systolic blood pressure (SBP) and FPG 
were normally distributed (p > 0.05). However, 
diastolic blood pressure (DBP) did not follow the 
pattern of normal distribution (p < 0.05). On the other 
hand, however, both SBP and DBP were not normally 
distributed among the controls. The results of One-
Sample Kolmogorov-Smirnov Test for the 
characteristics' distribution of both diabetics and 
controls are displayed in Table 2. 
Table 2: The pattern of distribution of the basic characteristics 
of subjects in both study groups using One- Sample 
Kolmogorov- Smirnov test. 
 
 
Age 
(years) 
Weight 
(kg) 
BMI 
(kg/m
2
) 
SBP 
(mmHg) 
DBP 
(mmHg) 
FPG 
(mmol/l) 
 
 
 
 
Diabetics 
(Group I) 
(n = 97) 
Mean 53.42 81.56 30.14 130 81 9.78 
SD 7.55 11.48 4.87 22 12 3.59 
Kolmogorov- 
Smirnov Z-
value 
1.06 0.73 0.69 1.04 1.65 1.10 
p-value 0.22 0.66 0.73 0.23 0.01* 0.18 
 
 
 
Non- 
diabetics 
(GroupII) 
(n = 95) 
Mean 51.04 74.48 27.73 124 81 4.41 
SD 8.00 17.04 6.22 16 8 0.59 
Kolmogorov- 
Smirnov Z-
value 
1.27 0.81 0.73 2.64 2.60 0.67 
p-value 0.08 0.52 0.67 <0.0001* <0.0001* 0.76 
BMI: body mass index; SBP: systolic blood pressure; DBP; diastolic blood pressure; FPG: 
fasting plasma glucose; SD: standard deviation. *p < 0.05 using One Sample Kolmogorov- 
Smirnov Test (two-tailed) indicates that variables are not normally distributed. 
 
The variables that were not normally 
distributed in either group of subjects were 
transformed to their Log10-values, and the One- 
Sample Kolmogorov Smirnov Test was repeated one 
more time. Log10 transformation did not succeed to 
normalize DBP and SBP values (p < 0.0001).There 
were no statistically significant differences in the mean 
age, sex distribution, smoking frequency and DBP 
between the two groups (p > 0.05 for all). Non- 
diabetic controls demonstrated significantly lower 
mean values of body weight, BMI, FPG and SBP 
(Table 3). 
Table 3: The basic clinical, anthropometric and biochemical 
characteristics of the diabetic and control subjects 
Parameter 
Group I 
(T2DM 
patients) 
(n= 97) 
Group II (Control 
subjects) 
(n = 95) p-Value 
mean ± SD or 
n (%) 
mean ± SD or n 
(%) 
Age (years) 53.42 ± 7.55 51.04 ± 8.00 0.05 
Sex 
Males 54 (55.67) 51 (53.68) 
0.40 
Females 43 (44.33) 44 (46.32) 
Body weight (Kg) 81.56 ± 11.48 74.48 ± 17.04 0.001 
BMI group 
(Kg/m
2
)  
< 25 14 (14.44) 37 (38.94) 
<0.01 25-30 35 (36.08) 25 (26.32) 
> 30 48 (49.48) 33 (34.74) 
BMI (Kg/m
2
) 30.14 ± 4.87 27.73 ± 6.22 0.003 
Hypertension 
Yes 60 (61.86) 35 (36.84) 
<0.001 
No 37 (38.14) 60 (63.16) 
SBP (mmHg)* 130.2 ± 22.8 124.9 ± 16.3 0.04 
DBP (mmHg)* 81.3 ± 12.3 81.1 ± 8.67 0.63 
Smoking 
Yes 44 (45.36) 32 (33.68) 
0.09 
No 53 (54.64) 63 (66.32) 
FPG (mmol/L) 9.78 ± 3.59 4.41 ± 0.59 <0.0001 
* Using Mann Whitney-U test. BMI: body mass index, SBP: systolic blood pressure, DBP: 
diastolic blood pressure, FPG: fasting plasma glucose. Hypertension was defined by 
having SBP≥ 140 mmHg and DBP ≥ 90 mmHg or use of antihypertensive drugs.  
Genotypes frequencies of Pro12Ala 
(rs1801282) among diabetic subjects and controls 
were within HWE [(2=0.35, p= 0.554) and ( 2=1.04, 
p= 0.308)] respectively. The comparisons of the allelic 
and genotypic frequencies of Pro12Ala mutation of 
PPAR-γ2 gene between diabetics and controls did not 
show any statistically significant differences [(
2
= 
1.99, p= 0.16) and (
2
= 2.17, p= 0.14)] respectively 
(Table 4). 
Table 4: Comparisons of allelic and genotypic frequencies of 
"Pro12Ala" polymorphism among diabetics and controls 
 
 Allelic Frequency 
n (%) 
Genotypic Frequency 
n (%) 
C 
(Pro) 
 
G 
(Ala) 
 
CC 
(Pro/Pro) 
 
GC 
(Pro/Ala) 
 
GG 
(Ala/Ala) 
 
Diabetic Patients 
(Group I) 
N = 97 
183 
(94.33) 
11 
(5.67) 
86 
(88.66) 
11 
(11.34) 
0 
(0.00) 
Non- Diabetics 
(Group II) 
N = 95 
172 
(90.53) 
18 
(9.47) 
77 
(81.05) 
18 
(18.95) 
0 
(0.00) 
p- value* 0.16 0.14 
*Using Chi-square test. 
 
The association of the mutant allele of the 
Pro12Ala polymorphism with T2DM was assessed 
using logistic regression analysis where diabetes was 
assigned as the dependent variable while Pro12Ala, 
age, sex, BMI and smoking were considered as the 
independent co-variables. The analysis demonstrated 
that having the Ala12 allele is not associated with 
T2DM (B= -0.16, P= 0.74). However, age, BMI and 
smoking were significantly associated with the 
development of diabetes in the study subjects (Table 
5). 
Table 5: Logistic regression analysis for the association of 
Pro12Ala mutation of PPAR-γ gene and other co- variables with 
T2DM 
 
Factor B- value p- value 
Pro12Ala gene variant -0.16 0.74 
Age -0.03 0.04 
Sex 0.02 0.63 
BMI -0.04 < 0.01 
Smoking -1.03 0.02 
*BMI: body mass index. The fitness of model was assessed by R- square estimation (R
2
 
was 0.45) and by Hosmer and Lemeshow test ( 2= 13.11, df=8, p-value= 0.11). 
 
The Odds' ratio and its 95
%
 confidence 
interval (95 % CI) for the association of Pro12Ala 
mutation with T2DM were calculated using Mantel- 
Haenszel test. The Pro12Ala was not associated with 
the risk of developing T2DM where Odd's ratio was 
0.55 (95% CI= 0.23-1.32, p= 0.14).  
The presence of the Ala12 allele was not 
associated with any significant differences in the 
mean values of body weight, FPG, SBP, DBP and 
BMI in both diabetics and non- diabetic subjects (p> 
0.05 for all). However, the Pro12Ala mutation was 
more prevalent among male non- people with 
diabetes compared to females in the same group 
(77.78% vs. 22.22%, p= 0.02). The genotypes 
distribution by BMI did not show significant differences 
between Pro/Pro and Pro/Ala carriers in the presence 
and absence of T2DM (p= 0.91 and 0.72 respectively) 
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(Table 6). 
 
 
Discussion 
 
The CCA to GCA variation at codon 12 of the 
PPAR-γ2 specific exon is a common sequence 
variation with a reduced functional capacity as a 
transcriptional factor for a large number of genes [21], 
[32]. The minor allele frequency of the Pro12Ala 
polymorphism of the PPAR-γ gene has found to vary 
widely across different populations worldwide with its 
lowest frequency being in people of East Asian 
descent and highest figures being in Caucasians [22]. 
In Iraq, and to best of our knowledge, this is the first 
study that investigates the distribution and the 
association of this common functional polymorphism 
with T2DM among adult Iraqi subjects of Arabic 
descent. Iraq is a multinational and a multi-ethnic 
country in North-West Asia. This study has focused on 
a populations' sample of 192 non- related Native 
Arabic adult Iraqis living in urban areas of Mosul, the 
biggest city of Ninevah Province which is the second 
largest province in Iraq.  
Table 6:  Comparisons of clinical, anthropometric and 
biochemical variables of people with diabetes and non- people 
with diabetes by their genotypes of Pro12Ala mutation 
 
 
Diabetics (Group I) 
(n = 97) 
Non- Diabetics 
(n =  95) 
Pro/Pro 
(n =  86) 
Pro/Ala 
(n = 11) 
p-
value 
Pro/Pro 
(n = 77) 
Pro/Ala 
(n = 18) 
p- 
value 
Sex 
Female 36 (41.9) 7 (63.64) 
0.17 
40 (51.9) 4 (22.22) 
0.02 
Male 50 (58.1) 4 (36.36) 37 (48.1) 14 (77.78) 
Body weight (Kg) 
82.06± 
11.71 
77.64± 
8.97 
0.16 
75.28± 
10.22 
74.29± 
18.32 
0.76 
BMI (Kg/m
2
) 
30.23± 
5.05 
29.40± 
3.12 
0.41 
27.76± 
6.56 
27.55± 
4.54 
0.80 
BMI 
Groups 
< 25 12 (85.71) 2 (14.29) 
0.91 
30 (81.08) 7 (18.92) 
0.72 25- 30 31 (88.57) 4 (11.43) 20 (76.92) 6 (23.08) 
≥ 30 43 (89.58) 5 (10.42) 27 (84.38) 5 (15.62) 
SBP (mmHg) 
129.9± 
23.0 
132.3± 
21.5 
0.60 
124.9± 
16.9 
125± 13.9 0.78 
DBP (mmHg) 81.4± 12.6 80.9± 9.7 0.97 81.0± 8.9 81.7± 7.9 0.82 
FPG (mmol/l) 9.87±3.66 
9.11± 
3.09 
0.40 4.51± 0.60 4.35± 0.53 0.62 
*Values are expressed as mean ± SD or n(%). Comparisons of continuous variables were 
made using unpaired Student's t-test (two-tailed) except for SBP & DBP which were 
compared using Mann Whitney U test. Sex distribution was assessed by Chi-square test 
while genotypes distribution by BMI was compared by Fisher's Exact test. 
 
We demonstrated lack of statistically 
significant differences in the allelic and genotypic 
frequencies of Pro12Ala mutation between diabetic 
patients and non- diabetic controls. The Odd's ratio of 
the association between diabetes and this mutation 
was not significant (p = 0.14). Moreover, the Pro12Ala 
polymorphism of the human PPAR gamma gene was 
not a significant independent factor in the aetiology of 
T2DM in our patients (p = 0.74).    
These results point towards lack of 
association between the mutant PPAR-γ2 gene 
variant and the development of T2DM among the 
studied sample of the Iraqi population. Similar to the 
findings of the current study, other researchers have 
also revealed no evidence of an association between 
Pro12Ala and diabetes among different European and 
Asian populations [33] [34] [35].  
Reports from our region, the Middle East, also 
showed this lack of association between diabetes and 
Pro12Ala. Among these is a study of Tunisian 
subjects by Zouari Boussaida et al. [26]. Also, in 
Qatar, Badii et al. have found that the frequency of the 
mutant allele of Pro12Ala among cases of T2DM did 
not differ significantly from that of controls and that the 
association of this polymorphism with diabetes was 
not significant among Qatari consanguineous 
population [36].  
Several previous studies elsewhere have 
demonstrated a significant association of the 
Pro12Ala polymorphism with T2DM. Ghoussaini et al. 
found a significant association between PPAR-γ 2 
Pro12Ala variant and T2DM [37]. The Pro12Ala 
polymorphism of PPARG gene contributed to the risk 
of developing T2DM in 554 Indian Sikhs according to 
a recent study [38]. More recently, a study in 2012 
revealed that genetic variants of PPAR-γ, ADIPOQ 
and HNF4A genes were individually and jointly 
associated with T2DM among Hong Kong Chinese 
people and that the Pro12 allele is the risk allele for 
both T2DM and coronary heart disease [39].  
Although a few studies only observed a higher 
Ala12 allele frequency among the diabetic patients 
compared to healthy controls conferring the possible 
"risky" contribution of the Ala12 allele, the association 
of the Pro12 allele of the PPAR-γ gene with diabetes 
mellitus was the basic finding of many other studies 
worldwide including an extensive meta- analysis 
involving 3000 individuals which showed a 1.25- fold 
increase in the diabetic risk upon having the wild-type 
allele [40] [41] [42] [43] [44] [45] [46]  [47] [48].   
While the exact mechanisms by which the 
Pro12Ala variant of PPAR-γ gene is associated with 
diabetes is not fully understood, it seems that the 
Ala12 allele improves the peripheral insulin sensitivity 
by reducing the release of insulin-desensitizing free 
fatty acids, tumor necrosis factor-alpha and resistin in 
addition to the increased release of adiponectin (an 
insulin-sensitizing hormone). These effects will 
ultimately enhance peripheral glucose uptake and 
inhibit the hepatic glucose production [16]. 
The inconsistency of the results of different 
association studies all over the world- including the 
current work- may be partially explained by the 
heterogeneity of the participant's ethnicity. It is 
assumed that around 14% of the between-studies 
variances may be attributed to differences in the 
ethnicity [21].  
Also, the differences in the allelic and the 
genotypic frequencies of the Pro12Ala gene variant 
among different populations, and thus their 
contribution to the Odd's ratio of this mutation as a 
predictor for T2DM may also be referred to the 
possible overestimation or underestimation of the 
mutations' frequency. Different scientists used 
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different genotyping techniques to investigate the 
mutation like PCR-RFLP, TaqMan probes, DHPLC 
and others which may have different sensitivities. 
Differences in the study designs and sample sizes 
may affect the results.  
Small sample size in some studies- including 
this one- may affect the power of the statistical 
analyses. For this purpose, we conducted a Post- hoc 
analysis to compute the achieved power of the study 
using the G*Power software 3.0.10 (Exact- 
proportions). The power was 0.69 assuming an 
expected rate of the risky allele (Pro12) to be 0.95 
among people with diabetes and 0.85 among controls. 
Our small sample size, thus, represents a major study 
limitation that may affect our conclusions regarding 
the association of the polymorphism with diabetes and 
its subsequent impact on the diabetic phenotypes in 
our patients.  
Other possible influences that perhaps stand 
behind these discrepancies may be possible gene-
gene interactions and some gene-environmental 
(including gene-diet) interactions. Controls chosen to 
participate in many of the association studies 
including the current one may not have been selected 
so perfect. So many of these studies relied on self- 
reported controls with random glucose measurement 
to rule out diabetes. A better controls selection would 
probably require conducting oral glucose tolerance 
test (OGTT).  
These divergent results may also be 
explained by the possible effect of the Pro12Ala gene 
variation on other factors that contribute to the 
aetiology of diabetes like insulin secretion and/or 
action in response to free fatty acids and physical 
activity [49] [50]. People in our community are 
consuming a lot of fat in their diet and are currently 
experiencing a more westernised pattern of life than 
before with overtly reduced average daily physical 
activity. These interactions may attenuate the 
susceptibility to diabetes in the presence of the less 
risky Ala12 allele. For this reason, we highly 
recommend emphasising on having detailed 
information on diet and physical activity measures in 
parallel with the Pro12Ala mutation analyses in Iraqi 
people in the future investigations.  
PPAR-γ2 gene variant plays important roles in 
the adipocytes differentiation and energy metabolism. 
Its variants like Pro12Ala substitution are expected to 
be associated with obesity [51]. Our subjects carrying 
the Ala allele, whether diabetics or controls, got lower 
mean body weight and BMI respectively than those 
carrying the wild-type allele only although these 
comparisons did not reach the level of statistical 
significance. 
In our study, the differences in the frequency 
of the Ala12 allele by the BMI categories were not 
statistically significant and in comparison to lean 
subjects, obese subjects did not demonstrate a 
statistically significant lower frequency of the mutant 
allele (p = 0.74). Wang et al. indicated that the 
Pro12Ala variant of the PPAR-γ gene is associated 
with obesity in Chinese Han people. Their diabetic 
and non- diabetic carriers of Ala12 carriers were 
significantly leaner than non- Ala12 carriers. However, 
they demonstrated that the frequency of the Ala12 
allele was significantly lowest at BMI> 28 kg/m
2
 [44].  
Again the variance in the sample size (192 vs 
3146) can partially explain this inconsistent 
association of Pro12Ala gene polymorphism with 
obesity in both studies. Another reason can be the 
different definitions of obesity adopted by the two 
studies where our study relied on the BMI cut points 
by WHO [52] which are basically derived from data of 
Western population, while Wang et al. considered 
obesity at BMI≥ 28 kg/m
2
 and overweight at BMI ≥ 24 
kg/m
2
. Asians may have more cumulative risks for the 
development of cardiovascular diseases at these 
lower BMI values [53] [54].   
Despite that the current work demonstrated a 
lower mean BMI among (Ala) allele carriers with and 
without diabetes mellitus, there are some reports that 
non- diabetic carriers of the mutant allele of Pro12Ala 
gene variant may have a higher tendency to gain 
weight over time [36], [55]. Lindi et al. demonstrated 
that carrying the Ala12 allele would be rather in favour 
of increased insulin sensitivity and thus weight gain 
happens without the development of diabetes. In our 
study, the lower mean fasting glucose level among the 
diabetic and the non- diabetic heterozygotes 
compared to the wild-type homozygotes may reflect 
this improved insulin sensitivity and supports this 
hypothesis. However, direct measurement of insulin 
sensitivity (as by IVOGTT or hyperinsulinaemic 
euglycemic clamp) or its surrogate measurements 
(like by HOMA, or QUICKI) would better affirm this. 
PPAR-γ is an important player in blood 
pressure control [10].  In our study, the Pro/Ala 
heterozygotes demonstrated a higher mean value of 
SBP compared to the Pro/Pro homozygotes although 
this relation has not been adjusted for other 
independent risk factors like age and BMI as this 
comparison did not reach the level of significance. By 
our results, other investigators have demonstrated an 
association between the Ala12 allele and the elevation 
of systolic blood pressure and/or diastolic blood 
pressure [56] [57]. A reasonable explanation for this 
association between hypertension and Pro12Ala 
polymorphism is the one already suggested by 
Sugawara et al. [58] who showed that PPAR gamma 
activation could downregulate the expression of the 
angiotensin II receptor gene in the vascular smooth 
muscle cells among experimental animals. This effect 
may be abolished when the PPAR-γ protein loses a 
part of its transcriptional capacity upon having 
functional polymorphisms in its coding gene as in 
case of rs1801282.     
Our study revealed a relatively high frequency 
of the Ala12 allele and Pro/Ala genotype of Pro12Ala 
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polymorphism among Iraqi people of Arabic descent. 
However, these frequencies were not significantly 
different among diabetics and non- diabetic control 
subjects. The Pro12Ala mutation failed to predict 
T2DM in our subjects and did not behave as an 
independent risk factor for the development of 
diabetes possibly due to the limited study power 
because of the relatively small sample size. However, 
the risk of diabetes in our patients was evidently 
related to other independent variables like age, body 
mass index and smoking. Although non-significant, 
Ala12 carriers exhibited lower mean body weight and 
BMI regardless of diabetes. The lower mean blood 
glucose level among these subjects may reflect higher 
peripheral insulin sensitivity than what may Pro/Pro 
carriers have. Also, the Ala12 allele carriers may be 
prone to systolic hypertension possibly due to the 
reduced transcriptional capacity of the mutant PPAR-γ 
gene variant. 
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